Related Experiment Video
Updated: Mar 24, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.4K
Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?
Eduardo Pimenta1, David A Calhoun2,3
1Experimental Medicine CV/Hem, Clinical Sciences, Drug Discovery, Bayer Pharma AG, Aprather Weg 18a, Building 429, 42113, Wuppertal, Germany. eduardo.pimenta@bayer.com.
Current Hypertension Reports
|March 8, 2016
Summary
Resistant hypertension affects less than 5% of patients on optimized treatment. New drug development for this high cardiovascular risk group requires careful consideration of complex factors.
Area of Science:
- Cardiology
- Pharmacology
- Drug Development
Background:
- Resistant hypertension prevalence is lower than previously thought, affecting <5% of patients on optimized treatment.
- Despite lower prevalence, these patients face elevated cardiovascular risk, necessitating novel therapeutic strategies.
- Developing new antihypertensive agents is a complex, lengthy, and costly endeavor.
Purpose of the Study:
- To outline key factors for consideration in developing new therapeutic agents for resistant hypertension.
- To address the unmet need for effective treatments in a high-risk patient population.
Main Methods:
- Review of current literature on resistant hypertension prevalence and cardiovascular risk.
- Analysis of challenges and considerations in pharmaceutical drug development pipelines.
- Discussion of strategic factors for novel agent development targeting resistant hypertension.
Main Results:
- Optimized antihypertensive treatment effectively controls hypertension in most patients.
- A small percentage of patients (<5%) with resistant hypertension require specialized therapeutic approaches.
- Identifying and developing new agents for resistant hypertension is critical due to associated cardiovascular risks.
Conclusions:
- While resistant hypertension is less prevalent than once believed, it remains a significant clinical challenge.
- Effective therapeutic approaches are crucial for managing the increased cardiovascular risk in these patients.
- Strategic planning and consideration of development factors are essential for creating new treatments for resistant hypertension.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
827
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
827
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
3.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
01:30Heart Failure V: Medical Management
512
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
512
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K